TY  - BOOK
AU  - Elsarrag, Mazin 
TI  - Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications
SN  - 1386-341X
PY  - 2022///
KW  - *ACTH-Secreting Pituitary Adenoma
KW  - *Adenoma
KW  - *Pituitary Neoplasms
KW  - ACTH-Secreting Pituitary Adenoma/pa [Pathology]
KW  - Adenoma/pa [Pathology]
KW  - Adenoma/su [Surgery]
KW  - Humans
KW  - Pituitary Neoplasms/pa [Pathology]
KW  - Pituitary Neoplasms/su [Surgery]
KW  - World Health Organization
KW  - MedStar Washington Hospital Center
KW  - Ophthalmology Residency
KW  - Journal Article
N2  - CONCLUSIONS: The majority of null cell adenomas diagnosed under the 2004 WHO classification system are reclassified as gonadotroph or corticotroph adenomas under the 2017 WHO classification system. Rates of progression and recurrence between subtypes are not as different as previously believed at our institution and require a larger cohort to further investigate. Copyright © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature; METHODS: We constructed a database from all 239 patients who underwent resection of a non-functioning pituitary adenoma between 2003 and 2015 and had at least 5 years of follow-up. Pathologic diagnosis was determined under both the 2004 and 2017 WHO classification systems. We compared the rates of recurrence and progression between subtypes using univariate and multivariate Cox regression analyses; PURPOSE: Outcomes of patients with non-functioning pituitary adenomas categorized using the 2004 and 2017 WHO classification systems are understudied. We report outcomes from the University of Virginia of patients with non-functioning pituitary adenomas categorized using both systems; RESULTS: Nearly 30% of the tumors in our database were classified as null cell adenomas under the 2004 classification system, whereas only 10% of the tumors were classified as null cell adenomas using the 2017 classification system. Most of these tumors were reclassified as either corticotroph or gonadotroph adenomas. Despite our relatively large cohort and average follow-up of nearly 9 years, we did not detect a significant difference in recurrence and progression between subtypes
UR  - https://dx.doi.org/10.1007/s11102-022-01281-5
ER  -